COVID-19 Vaccine Group

Two Shot Same Day Exception Rules for COVID-19

For COVID-19 shots administered:

  • before 10/25/2021, the Duplicate Shot, Same Day rules do NOT apply because absolute minimum intervals between dose 1 and dose 2 = 0 days (before 10/25/2021) in both the Pfizer COVID-19 2-dose series and Moderna COVID-19 2-dose series. 
  • on or after 10/25/2021, the Duplicate Shot, Same Day rules apply because absolute minimum intervals between dose 1 and dose 2 > 0 days (on or after 10/25/2021) in both the Pfizer COVID-19 2-dose series and Moderna COVID-19 2-dose series. 


Table of Contents

COVID-19 Vaccine Group Evaluation and Forecasting Rules

General Rules for COVID-19

General rules are not series-specific; general rules apply to the entire vaccine group.

Rules for Recommending at the CVX Code vs. Vaccine Group Level 

  • If the patient has no shots on record, 
    • and is < 5 years old, recommend CVX 218 at 5 years old.
    • and is > = 5 years old and < 12 years old, recommend CVX 218 at today's date. 
    • and is > = 12 years old, recommend at the vaccine group level at today's date. 
  • If the patient has shots on record and the series is not complete,
    • and is < 5 years old, recommend CVX 218 at 5 years old.
    • and is > = 5 years old and < 12 years old (or will be < 12 years old at the recommended due date), recommend CVX 218 for the next target dose.
    • and is > = 12 years old (or will be >= 12 years old at the recommended due date) and < 18 years old,  recommend at the vaccine group level for the next target dose. 
    • and is > = 18 years old and is in the following series:
      • Pfizer COVID-19 2-dose Series, recommend at the vaccine group level for the next target dose.
      • Moderna COVID-19 2-dose Series, recommend at the vaccine group level for the next target dose.
      • Janssen COVID-19 1-dose Series, recommend at the vaccine group level for the next target dose. 

Series Completion Special Rule

  • Once a patient completes:
    • the Pfizer COVID-19 2-dose series, Moderna COVID-19 2-dose series, a COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, 
      • recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (12 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.  
      • and receives an additional dose1, the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
      • and receives a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.
    • the Pfizer COVID-19 (5-17) 2-dose series, 
      • and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (12 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE
      • and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK. 
      • and receives an additional dose1, the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
      • and receives a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.
    • the Janssen COVID-19 1-dose series, 
      • and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), along with recommendation reason code BOOSTER_DOSE.  
      • and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK. 
      • and receives a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.

Rules for an Additional Dose1

  • If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 2-dose series, Moderna COVID-19 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives an additional shot of CVX 208, CVX 217, CVX 207, or CVX 213:
    • at < 28 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 5 months required for a Booster Dose."
    • at >= 28 days and < 5 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for a Booster Dose."
    • at >= 5 months after series completion, then evaluate the shot as Valid. 
  • If a patient is >= 5 years old, completes a COVID-19 vaccine series via the Pfizer COVID-19 (5-17) 2-dose series and receives an additional shot of CVX 218, CVX 208, CVX 217, CVX 207, or CVX 213:
    • at < 28 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 5 months required for a Booster Dose."
    • at >= 28 days and < 5 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for a Booster Dose."
    • at >= 5 months after series completion, then evaluate the shot as Valid. 

Rules for Booster Dose2

Any of the FDA-Approved COVID-19 vaccines (except CVX 218) can be used for booster vaccination, regardless of the vaccine product used for primary vaccination. When a heterologous or “mix and match” booster dose is administered, the eligible population and dosing intervals are those of the vaccine used for primary vaccination.

Recommendation Rules for Booster Dose

  • Recommend at the Vaccine Group Level (along with recommendation reason code BOOSTER_DOSE)
  • Recommended Age = 12 years
  • Minimum Age = 12 years
  • Recommended Interval
    • After completion of Pfizer 2-dose series, Moderna 2-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine = 5 months
    • After completion of Janssen 1-dose series = 8 weeks

Evaluation Rules for Booster Dose

  • Any of the FDA-Approved COVID-19 vaccines (except CVX 218) are allowed for the Booster Dose.
  • Absolute Minimum Interval = 0 days
  • If a patient completes a COVID-19 vaccine series via the Pfizer 2-dose series, Moderna 2-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a Booster Dose2 of CVX 208, CVX 217, CVX 207, CVX 212, or CVX 213: 
    • at < 28 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 5 months required for a Booster Dose."
    • at >= 28 days and < 5 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for a Booster Dose."
    • at >= 5 months after series completion, then evaluate the shot as Valid. 
  • If a patient completes a COVID-19 vaccine series via the Janssen 1-dose series and receives a Booster Dose2 of CVX 208, CVX 217, CVX 207, CVX 212, or CVX 213:
    • at < 8 weeks after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for a Booster Dose."
    • at >= 8 weeks after series completion, then evaluate the shot as Valid.

Rules for Extra Shots After Additional Dose1and/or Booster Dose2

  • For patients that completed the Pfizer COVID-19 2-dose series, Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE. 
  • For patients that completed the Pfizer COVID-19 Child (5-17) 2-dose Series, 
    • is < 5 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
    • is > = 5 years old and < 12 years old and received an Additional Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
    • is > = 12 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE. 
  • For patients that completed the Moderna COVID-19 2-dose series, Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE. 
  • For patients that completed Janssen COVID-19 1-dose series and Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE. 
  • For patients that completed either the 1) COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a 2) COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, Additional Dose and/or Booster Dose, any shots administered after the primary series is evaluated as Accepted/EXTRA_DOSE.

Notes

  • 1Additional Dose - Defined by ACIP to be a dose administered when the immune response to a standard primary vaccine series is likely not to be protective. 
  • 2Booster Dose - Defined by ACIP to be a dose administered to restore protection after the effectiveness of protection from the primary series has declined. 

COVID-19 Vaccines

CVX Code

Name

Absolute Minimum AgeAbsolute Maximum AgeCounts towards U.S. Vaccination
207

Moderna COVID-19 Vaccine

0 days
Yes

208

Pfizer COVID-19 Vaccine

0 days
Yes
210AstraZeneca COVID-19 Vaccine0 days
Yes, only if all recommended doses are administered.
211Novavax COVID-19 Vaccine0 days
Yes, only if all recommended doses are administered.
212Janssen COVID-19 Vaccine0 days
Yes
213SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED0 days
Yes
217Pfizer COVID-19 Vaccine0 days
Yes
218Pfizer COVID-19 Vaccine (5-11 years)0 days18 years minus 1 dayYes

500

COVID-19 Non-US Vaccine, Product Unknown 



No

501

COVID-19 IV Non-US Vaccine (QAZCOVID-IN)



No

502

COVID-19 IV Non-US Vaccine (COVAXIN)

0 days
Yes, only if all recommended doses are administered.

503

COVID-19 LAV Non-US Vaccine (COVIVAC)



No

504

COVID-19 VVnr Non-US Vaccine (Sputnik Light)



No

505

COVID-19 VVnr Non-US Vaccine (Sputnik V)



No

506

COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)



No

507

COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences)



No

508

COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)



No

509

COVID-19 PS Non-US Vaccine (EpiVacCorona)



No

510

COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)

0 days
Yes, only if all recommended doses are administered.

511

COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)

0 days
Yes, only if all recommended doses are administered.

Combination Vaccines that Include COVID-19

No combination vaccines exist, at this time, that include COVID-19 and count toward completion of the Pfizer COVID-19 2-dose series.


CVX Code Specific Rules

CVX Code Absolute Minimum Age

  • If one of the CVX codes in the table above is administered below the absolute minimum age for that CVX code, then the Evaluation is Invalid and the reason code is BELOW_MINIMUM_AGE_VACCINE

CVX Code Absolute Maximum Age

  • If one of the CVX codes in the table above is administered above the absolute maximum age for that CVX code, then the Evaluation is Invalid and the reason code is ABOVE_MAXIMUM_AGE_VACCINE.

Rule for CVX 213

  • If the patient receives CVX 213 for:
    • Target Dose 1, evaluate the shot as Valid.
      • Recommended interval = 28 days
      • Recommended age = 5 years
    • Target Dose 2, evaluate the shot as Valid. 
    • If the patient receives CVX 213 for Target Dose 1 and CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
      • evaluate Target Dose 2 (CVX 212) as Valid.
      • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

Rules for COVID-19 Vaccines Not Authorized by FDA2

The following set of rules apply to 1) COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO and, 2) COVID-19 Vaccines Not Authorized by FDA or WHO, but is an Active COVID-19 Vaccine Candidate as part of a U.S.-based Clinical Trial of a COVID-19 Vaccine. 

  • The list of COVID-19 Vaccines Not Authorized by the FDA, but Authorized by the WHO are:

    • CVX 210 - AstraZeneca COVID-19 Vaccine

    • CVX 510 - BIBP, Sinopharm COVID-19 Vaccine
    • CVX 511 - CoronaVac, Sinovac
    • CVX 502 - COVAXIN
    • CVX 211- Novavax COVID-19 Vaccine
  • The list of COVID-19 Vaccines Not Authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine are:

    • Note - Currently, there are no COVID-19 vaccines that fall into this category. 
  • If the patient has received all recommended doses of the COVID-19 vaccine, then: 
    • Evaluate the shots as Valid; (Absolute Minimum Interval = 0 days; Absolute Minimum Age = 0 days)
    • Recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months), along with recommendation reason code BOOSTER_DOSE.  
  • If the patient has received one or more doses, but has not received all the recommended doses for that COVID-19 vaccine, then:
    • Evaluate the shot(s) as Valid.
    • Recommendation:
      • If one of the above listed COVID-19 vaccine is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days) or at 5years old, whichever date is later, in addition to returning recommendation reason code SUPPLEMENTAL_TEXT; Descriptive Text: "The vaccine administered should be a single dose of a Pfizer COVID-19 vaccine."
      • Once the patient has received the recommended COVID-19 vaccine, the series is complete. Recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months), along with recommendation reason code BOOSTER_DOSE. 


The following set of rules apply to COVID-19 Vaccines Not Authorized by FDA or WHO. 
  • The list of COVID-19 Vaccines Not Authorized by the FDA or WHO are:

    • CVX 500 - COVID-19 Non-US Vaccine, Product Unknown 
    • CVX 501 - COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
    • CVX 503 - COVID-19 LAV Non-US Vaccine (COVIVAC) 
    • CVX 504 - COVID-19 VVnr Non-US Vaccine (Sputnik Light) 
    • CVX 505 - COVID-19 VVnr Non-US Vaccine (Sputnik V)
    • CVX 506 - COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)
    • CVX 507 - COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences)
    • CVX 508 - COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
    • CVX 509 - COVID-19 PS Non-US Vaccine (EpiVacCorona)
  • If the patient has received a COVID-19 vaccine not authorized by the FDA or WHO for all or some or the recommended doses of the COVID-19 vaccine, then: 
    • Evaluate the shot(s) as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO. 
    • Recommendation:
      • If one of the above listed COVID-19 vaccine is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days) or at 5 years old, whichever date is later.  
        • Example #1: Patient has 1 shot of CVX 501 on record.
          • Evaluate CVX 501 as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO.
          • Recommend COVID-19 at the vaccine group level for Target Dose 1 at CVX 501 + recommended interval (28 days). 
        • Example #2: Patient has 1 shot of CVX 208 (Pfizer), then 1 shot of CVX 501 on record. 
          • Evaluate CVX 208 as Valid and CVX 501 as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO.
          • Recommend COVID-19 at the vaccine group level for Target Dose 2 at CVX 501 + recommended interval (28 days). 
      • If one of the above listed COVID-19 vaccine is NOT the last COVID-19 shot administered, recommend based on the series that applies for the last COVID-19 shot administered.
        • Example: If CVX 208 (Pfizer) is given after CVX 501, then recommend based on the Pfizer COVID-19 2-dose Series.

Notes

Immunization Series and Selection Rules

Series Name

  • Pfizer COVID-19 Child (5-17) 2-dose Series
  • Pfizer COVID-19 2-dose Series
  • Moderna COVID-19 2-dose Series
  • Janssen COVID-19 1-dose Series

Series Selection Rules

There are four series for this vaccine group: the Pfizer COVID-19 Child (5-17) 2-dose Series, Pfizer COVID-19 2-dose series, Moderna COVID-19 2-dose series, and Janssen COVID-19 1-dose series. The rules for determining which series applies are:

  • If patient is < 18 years and
    • dose 1 is CVX 212, then the Janssen COVID-19 1-dose series applies.
    • Otherwise, the Pfizer COVID-19 Child (5-17) 2-dose series applies. 
  • If the patient is >= 18 years and
    • dose 1 is CVX 208 or CVX 217, then the Pfizer COVID-19 2-dose series applies. 
    • dose 1 is CVX 207, then the Moderna COVID-19 2-dose series applies. 
    • dose 1 is CVX 212, then the Janssen COVID-19 1-dose series applies. 
    • dose 1 is CVX 213, reference the "Rule for CVX 213" rules above. 

Immunization Series: Pfizer COVID-19 Child (5-17) 2-dose Series  

The Pfizer COVID-19 Child (5-17) 2-dose Series is complete after 2 doses. 

Vaccine Dose Parameters - Minimum and Routine Ages 

Dose

Series Name

Absolute Minimum
 Age

Minimum Age

Routine
Age

Latest Recommended Age (less than)

Valid CVX Code(s) per Dose for this SeriesInvalid CVX Code(s) per Dose for this Series

1

Pfizer COVID-19 Child (5-17) 2-dose Series


0 days

5 years


5 years

N/A

218, 208, 217, 207, 213

N/A

2

Pfizer COVID-19 Child (5-17) 2-dose Series

0 days

5 years


5 years


N/A218, 208, 217, 207, 213

N/A


Vaccine Dose Parameters - Minimum and Recommended Intervals

Doses

Series Name

Absolute Minimum Interval

Minimum Interval

Recommended Interval

Latest Recommended Interval (less than)

Dose 1 to 2

Pfizer COVID-19 Child (5-17) 2-dose Series

17 days 

21 days

21 days

N/A

Series Special Rules

  • If the patient receives a shot at < 5 years old, evaluate the shot as Valid, with reason code SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age."

Rule for CVX 212 (Janssen COVID-19 Vaccine)

  • If CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
    • evaluate Target Dose 2 (CVX 212) as Valid.
    • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

Rule for CVX 207 (Moderna COVID-19 Vaccine) Administered < 18 years old

  • If the patient is administered Moderna COVID-19 vaccine (CVX 207):
    • between ages >= 5 years and < 12 years 
      • for Target Dose 1, evaluate the shot as Valid. Recommend CVX 218 for Target Dose 2 at Dose 1 + recommended interval (28 days).
      • for Target Dose 2, evaluate the shot as Valid. Recommend based on the Series Completion Special Rule
    • between ages >= 12 years and < 18 years 
      • for Target Dose 1, evaluate the shot as Valid. Recommend at the vaccine group level for Target Dose 2 at Dose 1 + recommended interval (28 days).
      • for Target Dose 2, evaluate the shot as Valid. Recommend based on the Series Completion Special Rule

Immunization Series: Pfizer COVID-19 2-dose Series

The Pfizer COVID-19 2-dose series is complete after 2 doses. 

Vaccine Dose Parameters - Minimum and Routine Ages 

Dose

Series Name

Absolute Minimum
 Age

Minimum Age

Routine
Age

Latest Recommended Age (less than)Valid CVX Code(s) per Dose for this SeriesInvalid CVX Code(s) per Dose for this Series

1

Pfizer COVID-19 2-dose Series

18 years

18 years18 yearsN/A

208, 217, 213

N/A

2

Pfizer COVID-19 2-dose Series

18 years

18 years

18 years

N/A208, 217, 207, 213N/A

Vaccine Dose Parameters - Minimum and Recommended Intervals

Doses

Series Name

Absolute Minimum Interval

Minimum Interval

Minimum Recommended Interval

Latest Recommended Interval (less than)

Dose 1 to 2

Pfizer COVID-19 2-dose Series

0 days if dose 2 administered < 10/25/2021

17 days if dose 2 administered >= 10/25/2021

21 days

21 days

N/A

Series Special Rules

Rule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))

  • If the patient is >= 18 years old and administered Pfizer COVID-19 Vaccine (CVX 218):
    • as Target Dose 1 or Target Dose 2, evaluate as Invalid/ ABOVE_MAXIMUM_AGE_VACCINE. 

Rule for CVX 212 (Janssen COVID-19 Vaccine)

  • If CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
    • evaluate Target Dose 2 (CVX 212) as Valid.
    • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

Immunization Series: Moderna COVID-19 2-dose series

The Moderna COVID-19 2-dose series is complete after 2 doses. 

Vaccine Dose Parameters - Minimum and Routine Ages 

Dose

Series Name

Absolute Minimum
 Age

Minimum Age

Routine
Age

Latest Recommended Age (less than)

Valid CVX Code(s) per Dose for this SeriesInvalid CVX Code(s) per Dose for this Series

1

Moderna COVID-19 2-dose Series

18 years - 4 days 

18 years

18 years

N/A207, 213

N/A


2

Moderna COVID-19 2-dose Series

18 years - 4 days 18 years18 yearsN/A207, 208, 217, 213

N/A


Vaccine Dose Parameters - Minimum and Recommended Intervals

Doses

Series Name

Absolute Minimum Interval

Minimum Interval

Recommended Interval

Latest Recommended Interval (less than)

Dose 1 to 2

Moderna COVID-19 2-dose Series

0 days if dose 2 administer < 10/25/2021

24 days if dose 2 administered >= 10/25/2021

28 days

28 days

N/A

Series Special Rules

Rule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))

  • If the patient is >= 18 years old and administered Pfizer COVID-19 Vaccine (CVX 218):
    • as Target Dose 1 or Target Dose 2, evaluate as Invalid/ ABOVE_MAXIMUM_AGE_VACCINE. 

Rule for CVX 212 (Janssen COVID-19 Vaccine)

  • If CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
    • evaluate Target Dose 2 (CVX 212) as Valid.
    • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

Immunization Series: Janssen COVID-19 1-dose Series

The Janssen COVID-19 1-dose Series is complete after 1 dose.

Vaccine Dose Parameters - Minimum and Routine Ages 

Dose

Series Name

Absolute Minimum
 Age

Minimum Age

Routine
Age

Latest Recommended Age (less than)

Valid CVX Code(s) per Dose for this SeriesInvalid CVX Code(s) per Dose for this Series

1

Janssen COVID-19 1-dose Series

0 days

18 years

18 years

N/A212

N/A


Series Special Rules

  • If the patient receives a shot at < 18 years - 4 days of age, evaluate the shot as Valid, with reason code SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age and/or minimum interval."